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ABSTRACT Pathogen cell-free DNA (pcfDNA) in blood and urine is an attractive
biomarker; however, the impact of preanalytical factors is not well understood.
Blood and urine samples from healthy donors spiked with cfDNA from Mycobacte-
rium tuberculosis, Salmonella enterica, Aspergillus fumigatus, and Epstein-Barr virus
(EBV) and samples from tuberculosis patients were used to evaluate the impact of
blood collection tube, urine preservative, processing delay, processing method,
freezing and thawing, and sample volume on pcfDNA. The PCR cycle threshold (CT)
was used to measure amplifiable cfDNA. In spiked samples, the median CT values for
M. tuberculosis, S. enterica, and EBV cfDNA were significantly lower in blood collected
in K2EDTA tubes than those in Streck and PAXgene blood collection tubes, and they
were was significantly lower in urine preserved with EDTA (EDTA-urine) than in urine
preserved with Streck reagent (Streck-urine). Blood and urine samples from TB pa-
tients preserved with K2EDTA and Tris-EDTA, respectively, showed significantly lower
median M. tuberculosis CT values than with the Streck blood collection tube and
Streck urine preservative. Processing delay increased the median pathogen CT values
for Streck and PAXgene but not K2EDTA blood samples and for urine preserved with
Streck reagent but not EDTA. Double-spin compared with single-spin plasma separa-
tion increased the median pathogen CT regardless of blood collection tube. No dif-
ferences were observed between whole urine and supernatant and between fresh
and thawed plasma and urine after 24 weeks at –80°C. Larger plasma and urine vol-
umes in contrived and patient samples showed a significantly lower median M. tu-
berculosis CT. These findings suggest that large-volume single-spin K2EDTA-plasma
and EDTA-whole urine with up to a 24-h processing delay may optimize pcfDNA de-
tection.
KEYWORDS cell-free DNA, liquid biopsy, PCR, preanalytical
Analysis of cell-free DNA (cfDNA) in the acellular fraction of plasma and urine, alsoknown as “liquid biopsy,” has emerged in the past decade as a promising new
modality for noninvasive testing for conditions such as prenatal genetic abnormalities
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(1) and cancer driver mutations (2, 3). In the field of infectious diseases, the detection
of Epstein-Barr virus (EBV) cfDNA in plasma has been in clinical use for several decades
as a screening and prognostic test for EBV-associated nasopharyngeal carcinoma (4, 5).
EBV cfDNA in plasma has been shown to be superior to cellular EBV as a marker
of EBV-related diseases, particularly, posttransplant lymphoproliferative disorder (6).
Pathogen cfDNA has also been applied to diagnose invasive infectious diseases. A
number of studies have reported on the performance of targeted cfDNA assays for the
diagnosis of tuberculosis (TB) (7–12), invasive fungal infections (13–16), and invasive
parasitic infections (17). More recently, metagenomic next-generation sequencing of
plasma cfDNA was evaluated in patients with bloodstream infection, cardiac surgery-
associated Mycobacterium chimaera infection, and invasive fungal infection (18–22).
Despite the growing interest, it is unclear how the biology and immunopathogenesis
of each pathogen impact the availability of its cfDNA as a diagnostic biomarker.
Furthermore, although noninvasive diagnosis of infectious diseases using cfDNA is an
attractive premise, particularly in resource-poor settings, further research is needed to
optimize preanalytical and analytical variables to define best practices and maximize
assay performance (23).
In the field of oncology and obstetrics, much progress has been made in investi-
gating and optimizing preanalytical factors that negatively impact the analysis of tumor
and fetal cfDNA, respectively. Rapid processing of blood within 6 h of collection and
using the standard K2EDTA blood collection tube were shown to be essential for
preventing the dilution of tumor cfDNA with genomic DNA (gDNA) due to postcollec-
tion lysis of white blood cells (WBCs) (24–26). Fetal cfDNA was shown to remain stable
up to 24 h at room temperature after blood collection in a K2EDTA blood collection
tube (27). The storage of blood in K2EDTA tubes at 4°C was insufficient to prevent the
dilution of tumor cfDNA (25). To mitigate tumor and fetal cfDNA dilution, cfDNA blood
collection tubes, such as Cell-Free DNA BCT (Streck, Omaha, NE), the PAXgene blood
circulating cell-free DNA (ccfDNA) tube (Qiagen, Germantown, MD), and a CellSave
preservative tube (CellSearch, Huntington Valley, PA), have been developed and com-
mercialized to stabilize WBCs ex vivo and enable delayed blood processing at room
temperature up to 7 days without compromising tumor cfDNA fraction (24–26, 28).
Similarly, urine preservatives, such as the Streck Cell-Free DNA urine preserve, has been
developed to preserve cfDNA. The separation of plasma from the cellular fraction using
double-spin versus single-spin methods has been shown to reduce the dilution of
tumor cfDNA (26). Studies have also positively correlated the yield of tumor cfDNA to
plasma volume used for extraction (26). Whether these reagents and processing
methods uniformly apply to pathogen cfDNA is unclear. Unlike tumor cfDNA assays,
which are designed to detect mutant allele in an abundant background of wild-type
allele, targeted pathogen nucleic acid amplification tests (NAATs) are designed to
amplify a highly specific pathogen sequence with no competition from a “wild type
allele.” Thus, rapid processing, double-spin plasma separation, and stabilization of
WBCs using expensive reagents and complex methods may not be critical for pathogen
cfDNA. However, other preanalytical factors, such as sample volume, may be equally
vital to the sensitive detection of pathogen cfDNA.
The aim of this study was to use contrived and clinical samples to investigate the
impact of preanalytical variables, such as type of blood collection tube or urine
preservative, processing delay, processing method, freezing and thawing, and sample
volume on pathogen cfDNA detection in plasma and urine.
MATERIALS AND METHODS
Ethics. This study was approved by the institutional review board at Stanford University. Approval for
the collection of clinical samples was obtained from the institutional review board at the Federal
University of Grande Dourados (UFGD) and the Comissão Nacional de Ética em Pesquisa in Brazil, the
Stellenbosch University Faculty of Health Sciences Research Ethics Committee (N14/10/136) in South
Africa, the Committee on Human Research at the University of California, San Francisco (UCSF), the
Research Ethics Committee at the Makerere University School of Medicine Research, and the Uganda
National Council for Science and Technology. All participants were 18 years of age and provided
written informed consent.
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Study design. Spiking experiments with pathogen cfDNA from Mycobacterium tuberculosis, Salmo-
nella enterica, Aspergillus fumigatus, and Epstein-Barr virus (EBV) were performed with fresh blood and
urine from healthy donors to evaluate the impact of (i) blood collection tube and urine preservative, (ii)
processing delay, (iii) processing method, (iv) freezing and thawing, and (v) sample volume on pathogen
cfDNA in plasma and urine. Blood and urine from pretreatment TB patients collected under a different
protocol at each site were used to validate findings from spiking experiments. A schematic overview of
the study design is shown in Fig. 1.
Study participants. Ten healthy health care workers (5 females and 5 males between 23 and
46 years old of White, Asian, and Middle Eastern race) with no symptoms or signs of infection were
recruited from the clinical laboratories at Stanford Health Care for blood and urine collection. Patients
with confirmed pulmonary tuberculosis (TB) based on culture and/or the Xpert MTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) were recruited from UFGD hospital and mass screening studies in the Dourados
prison in Brazil for blood collection, the Kiruddu Hospital and Kisenyi Healthcare Center level IV in
Uganda for urine collection, and the Scottsdene and Wallacedene Community Health Centres in South
Africa for blood collection.
Pathogen cfDNA preparation. Based on the fact that eukaryotic plasma cfDNA is 168 bp and that
bacterial cfDNA in a septic patient was shown to be slightly shorter than 168 bp, we aimed to generate
200-bp cfDNA fragments for the spiking studies (29, 30). Genomic DNA from M. tuberculosis and S.
enterica was extracted with a QIAamp DNA minikit (Qiagen), and A. fumigatus DNA was extracted with
FIG 1 Study design. Spiking experiments with pathogen cfDNA from M. tuberculosis (Mtb), S. enterica (Salmonella),
A. fumigatus (Aspergillus), and Epstein-Barr virus (EBV) were performed with fresh blood and urine from healthy
donors to evaluate the impact of blood collection tube and urine preservative (blue circle), processing delay (brown
circle), processing method (purple circle), sample storage (orange circle), and sample volume (red circle) on
pathogen cfDNA in plasma and urine. In addition to using contrived samples, blood collection tube and urine
preservative (blue circle) and sample volume (red circle) were evaluated using blood and urine samples from TB
patients.
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PrepMan Ultra sample preparation reagent (Applied Biosystems, Foster City, CA). DNA was digested with
Fragmentase (New England BioLabs, Ipswich, MA), according to the manufacturer’s instructions. DNA
fragments were separated on a 1.2% agarose gel using electrophoresis, and the region corresponding to
200 bp was cut and gel purified using the Wizard SV gel and PCR clean-up system (Promega, Madison,
WI). A plasma sample from an infected patient containing naturally occurring EBV cfDNA at 2,000 IU/ml
was used directly. DNA extracts and the plasma sample were serially diluted 1:10 in water, 3 l of each
dilution was spiked into 1 ml of donor plasma and urine, and the entire volume was extracted with the
Maxwell RSC ccfDNA plasma kit (Promega) on the Maxwell RSC system. Real-time PCR was performed
using the primers and probes shown in Table S1 in the supplemental material. PCRs consisted of 0.5 M
each primer and 0.2 M each probe, 5 l of 2 FastStart TaqMan Probe mastermix (Roche Applied
Science, Indianapolis, IN), and 3 l of DNA extract. The total volume was 10 l per reaction. The reactions
were run on a magnetic induction cycler (Bioline, Taunton, MA), with the following cycling parameters:
95°C for 10 min and 45 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Detection was performed
in the green, yellow, orange, and red channels at 72°C. The threshold was set at 0.2 for all channels. The
dilution that produced a cycle threshold (CT) between 25 and 30 was chosen for spiking experiments.
Aliquots were stored at –20°C and thawed only one time for spiking studies.
cfDNA spiking. Within 10 min of blood and urine collection, samples were spiked with pathogen
cfDNA at 3 l per ml of blood and urine and gently mixed.
Blood collection tube and urine preservative. For spiking experiments, venipuncture blood was
collected in three sets of K2EDTA (Becton, Dickinson, Franklin Lakes, NJ), Streck Cell-Free DNA BCT
(Omaha, NE), and PAXgene blood ccfDNA (PreAnalytiX GmbH, Hombrechtikon, Switzerland) blood
collection tubes. TB patients in South Africa were drawn concurrently in K2EDTA and Streck tubes and
processed immediately. Plasma was frozen at –80°C and shipped to Stanford University for testing.
For an investigation of urine preservative in spiking experiments, urine collected in a collection cup
was immediately transferred to four sets of conical tubes for each preservative and raw urine specimen.
Urine specimens were treated with preservative to obtain a final concentration of 25 mM EDTA using 0.5
M EDTA (pH 7.6) stock (Sigma-Aldrich), 10 mM Tris-EDTA using 0.5 M Tris-HCl (pH 8.5), and 0.5 M EDTA
(pH 7.6) stock, and a 1:20 dilution of Streck Cell-Free DNA urine preserve. Urine from TB patients in
Uganda was preserved in 10 mM Tris-HCl–10 mM EDTA (pH 8.5) and Streck Cell-Free DNA urine preserve,
frozen at –80°C, and shipped to Stanford University for testing.
Processing delay. One set of blood collection tubes and urine specimens was immediately pro-
cessed. The second and third sets were processed after room temperature incubation periods of 6 and
24 h, respectively. All remaining procedures were identical for the three sets.
Processing method. For single-spin plasma separation, blood collection tubes were centrifuged at
500 g for 10 min at room temperature, and the plasma was transferred to a new tube. For double-spin
plasma separation, 1.5 ml of plasma was additionally centrifuged at 16,000 g for 10 min at room
temperature, and the supernatant was transferred to a new tube. For urine processing, whole urine was
centrifuged at 500 g for 10 min, and the supernatant was transferred to a new tube.
Fresh versus thawed. Plasma obtained through single-spin plasma separation and whole urine from
the spiking experiments were stored at –80°C for 1 and/or 24 weeks. Samples were thawed at room
temperature and extracted for comparison to fresh samples.
Sample volume. Blood collected in K2EDTA tubes and EDTA-urine from five healthy donors were
spiked with M. tuberculosis cfDNA at the highest detectable dilution (see “Pathogen cfDNA preparation,”
above) and at a 10-fold higher concentration. Blood was processed using single-spin centrifugation. One
and 4 ml of fresh EDTA-plasma and whole urine were extracted using the Maxwell RSC system. The
Maxwell RSC ccfDNA plasma kit and a custom Maxwell RSC large-volume ccfDNA kit available commer-
cially were used to extract 1 and 4 ml, respectively. Sample volume was also investigated in TB patients
using EDTA-plasma from patients in Brazil and Tris-EDTA-urine from patients in Uganda. After thawing
samples, blood samples were extracted with QIAamp circulating nucleic acid kit (Qiagen), and urine
samples were extracted with the Maxwell RSC system.
cfDNA measurement. Except for assessments of sample volume, 1 ml each of plasma and urine were
extracted at each time point using the Maxwell RSC ccfDNA plasma kit. The real-time PCR conditions
described above were used to determine CT values for M. tuberculosis, S. enterica, A. fumigatus, and EBV
in spiking experiments and M. tuberculosis in clinical samples. Each PCR was performed in singlicate. The
median CT values, a measure of amplifiable cfDNA, were compared between different conditions. Except
for fresh versus thawed experiments, all cfDNA extracts from the same individual’s plasma and urine were
tested in the same PCR run.
Statistical analysis. A nonparametric test, the Wilcoxon signed-rank test of medians, was used to
compare differences between paired results. The EDTA group was used as the comparator for all
analyses. All statistical tests were computed for a two-sided type I error rate of 5%. Statistical analyses
were performed using the Prism software (GraphPad, San Diego, CA).
RESULTS
Blood collection tube and urine preservative. A comparison of the standard
K2EDTA tube to two cfDNA blood collection tubes spiked with pathogen cfDNA and
processed identically for plasma separation and extraction showed a significantly lower
median CT value with K2EDTA tubes for M. tuberculosis and S. enterica than with Streck
and PAXgene tubes (Fig. 2A and B and Table S2). The median A. fumigatus CT was
significantly lower for K2EDTA tubes than with Streck tubes but only after 6- and 24-h
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processing delays (Fig. 2C). The median A. fumigatus CT was significantly lower for
PAXgene tubes than for K2EDTA tubes except for the 24-h processing delay with
double-spin plasma separation (Fig. 2C). The median EBV CT was lower for K2EDTA
tubes than for Streck and PAXgene tubes, but the difference was significant only
after 6- and 24-h processing delays for single- and/or double-spin plasma separa-
tion (Fig. 2D).
A comparison of three urine preservatives using urine specimens from healthy
donors spiked with pathogen cfDNA showed significantly lower median pathogen CT
values for 25 mM EDTA than with Streck urine preservative for all four pathogens at all
time points for whole urine (unspun) and/or urine supernatant (one spin), with the
exception of EBV, which was significantly lower only after 6- and 24-h processing delays
(Fig. 3 and Table S3). In many instances, 25 mM EDTA yielded a lower median CT than
did 10 mM Tris-EDTA, but this difference reached statistical significance only after 6-
and/or 24-h processing delays for whole urine and/or urine supernatant (Fig. 3).
Unpreserved (neat) urine consistently yielded a significantly higher median CT than
did 25 mM EDTA for all four pathogens at all time points, with the exception of A.
fumigatus, which was significant only after 6- and 24-h processing delays (Fig. 3 and
Table S3).
In patients with pulmonary TB and detectable M. tuberculosis cfDNA in plasma,
blood samples concurrently collected in K2EDTA and Streck tubes and processed
FIG 2 Comparison of blood collection tubes for recovery of pathogen cfDNA in plasma using contrived samples. (A to D) Blood was collected from 10 healthy
donors in a K2EDTA (EDTA) tube, Streck Cell-Free DNA BCT, and a PAXgene blood ccfDNA tube and spiked with short fragments of DNA from M. tuberculosis
(A), S. enterica (B), A. fumigatus (C), and EBV (D). Blood collection tubes were processed after 0-, 6-, and 24-h delays at room temperature, and plasma was
obtained using one-spin (1spin) and double-spin (2spin) separation. PCR was performed on cfDNA extracts. Bars show median CT, and whiskers show the CT
range. For each condition (processing time and plasma separation method), Streck and PAXgene tubes were compared to EDTA tubes. *, P 0.05; **, P 0.01.
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immediately showed significantly lower median M. tuberculosis CT values with K2EDTA-
plasma than with Streck-plasma (P 0.021) (Fig. 4A and Table S4). In patients with
pulmonary TB and detectable M. tuberculosis cfDNA in urine, urine samples concur-
rently preserved with 10 mM Tris-EDTA and Streck urine preserve showed significantly
FIG 3 Comparison of urine preservatives for recovery of pathogen cfDNA using contrived samples. (A to D) Urine was collected from 10 healthy donors and
preserved with 25 mM EDTA, 10 mM Tris-EDTA, or Streck Cell-Free DNA urine preserve, or left unpreserved (neat urine) and spiked with short fragments of DNA
from M. tuberculosis (A), S. enterica (B), A. fumigatus (C), and EBV (D). Urine samples were processed after 0-, 6-, and 24-h delays at room temperature. Whole
urine (unspun) and urine supernatant (1spin) were included. PCR was performed on cfDNA extracts. Bars show median CT, and whiskers show the CT range. In
the absence of amplification for S. enterica in neat urine, a CT of 45 was assigned. For each condition (processing time and urine processing method), Tris-EDTA,
Streck, and neat were compared to EDTA. *, P 0.05; **, P 0.01.
FIG 4 Comparison of blood collection tubes and urine preservatives for detection of M. tuberculosis
cfDNA in plasma and urine from patients with tuberculosis. (A and B) IS6110 PCR CT values are plotted
for plasma samples collected concurrently in K2EDTA and Streck Cell-Free DNA BCT (n 7) (A), and
urine samples concurrently preserved in Tris-EDTA and Streck Cell-Free DNA urine preserve (n 20)
(B). Results are shown for patients with detectable M. tuberculosis cfDNA with both collection tubes
and preservatives.
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lower median M. tuberculosis CT with 10 mM Tris-EDTA than with Streck urine preser-
vative (P 0.035) (Fig. 4B and Table S4).
Processing delay. Compared to immediate processing (i.e., 0-h delay) of blood
collection tubes for plasma separation, a delay of 6 and/or 24 h at room temperature
increased the median pathogen CT values of all four pathogens spiked in Streck and
PAXgene tubes after single- and/or double-spin plasma separation, although the
difference was only consistently significant for M. tuberculosis and S. enterica (Fig. 5 and
Table S5). Processing delays of 6 and 24 h with single-spin plasma separation did not
significantly change the median CT values of any of the four spiked pathogens in a
K2EDTA tube (Fig. 5 and Table S5).
For urine samples, processing delays of 6 and 24 h did not increase the median CT
values of any of the four pathogens in urine preserved with 25 mM EDTA and 10 mM
Tris-EDTA (Fig. 6 and Table S6). Preservation of urine with Streck preservative resulted
in a significant increase in median CT values of M. tuberculosis, S. enterica, and EBV after
6- and/or 24-h delays in unspun urine and/or urine supernatant (1 spin). With unpre-
served (neat) urine, the median CT increased significantly for M. tuberculosis, A. fumiga-
tus, and EBV, which was statistically significant after a 24-h delay in whole urine and/or
supernatant. In neat urine spiked with S. enterica, most samples had undetectable PCR
amplification at all time points.
Processing method. A comparison of single-spin and double-spin plasma separa-
tion methods showed lower median CT values of all four pathogens with single-spin
FIG 5 Impact of processing delay on recovery of pathogen cfDNA in plasma using contrived samples. (A to D) Blood was collected from 10 healthy donors in
a K2EDTA tube, Streck Cell-Free DNA BCT, and PAXgene blood ccfDNA tube and spiked with short fragments of DNA from M. tuberculosis (A), S. enterica (B),
A. fumigatus (C), and EBV (D). Blood collection tubes were processed after 0-, 6-, and 24-h delays at room temperature, and plasma was obtained using one-spin
(1spin) and double-spin (2spin) separation. PCR was performed on cfDNA extracts. The bars show the median CT, and whiskers show the CT range. For each
condition (blood collection tube and plasma separation method), 6- and 24-h processing delays were compared to 0 h. *, P 0.05; **, P 0.01.
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separation than with double-spin separation, except for A. fumigatus in K2EDTA and
Streck tubes after a 0-h processing delay (Fig. 7 and Table S7). The difference was
statistically significant for M. tuberculosis, S. enterica, and EBV at all three time points (0-,
6-, and 24-h processing delays) and with all three blood collection tubes, with the
exception of EBV, which was only significant with K2EDTA and PAXgene tubes. For A.
fumigatus, the difference was statistically significant only after 0- and 24-h processing
delays with the PAXgene tube.
A comparison of whole urine (unspun) to urine supernatant (one spin) showed no
consistent difference in median CT values of all four pathogens at all three time points
(0-, 6-, and 24-h processing delays) and with all three urine preservatives (Fig. S1 and
Table S8).
Fresh versus thawed. A comparison of fresh and thawed plasma after 1 and
24 weeks of storage at –80°C showed no significant difference in median CT values of
all four pathogens after immediate processing with all three blood collection tubes,
with the exception of S. enterica in a PAXgene tube (Fig. S2 and Table S9).
A comparison of fresh and thawed urine after 24 weeks of storage at –80°C showed
no difference in median CT values of all four pathogens after immediate processing with
all three urine preservatives (Fig. S3 and Table S10).
Sample volume. A comparison of small and large volumes of plasma and urine for
the detection of M. tuberculosis cfDNA using contrived samples (1 ml versus 4 ml) and
clinical samples from newly diagnosed TB patients (plasma, 0.5 ml versus 3.0 ml; urine,
1 ml versus 4 ml) showed a significantly lower median CT with larger volumes for both
plasma and urine (Fig. 8 and Table S11). In a fraction of contrived and clinical samples,
amplification was only detected with the larger sample volume (Fig. 8).
FIG 6 Impact of processing delay on recovery of pathogen cfDNA in urine using contrived samples. (A to D) Urine was collected from 10 healthy donors and
preserved with 25 mM EDTA, 10 mM Tris-EDTA, Streck Cell-Free DNA urine preserve, or left unpreserved (neat urine) and spiked with short fragments of DNA
from M. tuberculosis (A), S. enterica (B), A. fumigatus (C), and EBV (D). Urine samples were processed after 0-, 6-, and 24-h delays at room temperature. Whole
urine (unspun) and urine supernatant (1spin) were evaluated. PCR was performed on cfDNA extracts. The bars show median CT values, and whiskers show the
CT range. In the absence of amplification for S. enterica in neat urine, a CT of 45 was assigned. For each condition (urine preservative and urine processing
method) 6- and 24-h processing delays were compared to 0 h. *, P 0.05; **, P 0.01.
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DISCUSSION
The detection of pathogen cfDNA in plasma and urine potentially affords an
attractive novel noninvasive approach to diagnosing invasive infections. However, little
is known about the impact of preanalytical factors, such as type of blood collection
tube or urine preservative, processing delay, processing method, sample volume, and
freezing and thawing, on the detection of pathogen cfDNA (23). We showed that most
of the preanalytical factors deemed important for fetal and tumor cfDNA (24–26, 28) do
not seem to apply to pathogen cfDNA. These results increase the potential for low-cost
pathogen cfDNA assays to be developed for infectious disease diagnostics.
Using blood and urine samples spiked with cfDNA from four different pathogens
representative of bacteria, fungi, and DNA viruses, we showed the standard K2EDTA
blood collection tube, which is inexpensive and widely available, yields an amount of
detectable pathogen cfDNA higher than or equivalent to that of Streck and PAXgene
tubes, except for A. fumigatus cfDNA in PAXgene tubes. Importantly, the addition of
preservative to urine was critical to preventing the degradation of pathogen cfDNA,
and preservation with 25 mM EDTA was superior to Streck urine preservative. We were
also able to confirm the superiority of K2EDTA and 25 mM EDTA over Streck tubes using
plasma and urine, respectively, from patients with active TB. Similar to tumor cfDNA in
plasma (25), we showed that pathogen cfDNA in blood collected in K2EDTA and urine
preserved with 25 mM EDTA is stable for at least 24 h at room temperature. Unlike
tumor cfDNA, for which double-spin plasma separation helps prevent tumor cfDNA
FIG 7 Comparison of single-spin to double-spin plasma separation for recovery of pathogen cfDNA using contrived samples. (A to D) Blood was collected from
10 healthy donors in a K2EDTA tube, Streck Cell-Free DNA BCT, and PAXgene Blood ccfDNA tube and spiked with short fragments of DNA from M. tuberculosis
(A), S. enterica (B), A. fumigatus (C), and EBV (D). Blood collection tubes were processed after 0-, 6-, and 24-h delays at room temperature, and plasma was
obtained using one-spin (1spin) and double-spin (2spin) separation. PCR was performed on cfDNA extracts. Bars show median CT values, and whiskers show
the CT range. For each condition (blood collection tube and processing delay), double spin was compared to one spin. *, P 0.05; **, P 0.01.
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dilution after delayed processing (26), a single low-speed centrifugation was sufficient
to maximize the yield of spiked pathogen cfDNA up to 24 h after sample collection.
With urine samples, we showed that separation of cellular fraction from whole urine
with a centrifugation step had no impact on the yield of pathogen cfDNA up to 24 h
after urine collection. In agreement with tumor cfDNA, extraction of a higher volume of
plasma and urine yielded a higher abundance of M. tuberculosis cfDNA in contrived
samples and samples collected from TB patients. Last, freezing and thawing of plasma
and urine samples after storage at –80°C up to 24 weeks did not have any impact on
the abundance of pathogen cfDNA in spiked samples.
Our findings bear implications for the application of pathogen cfDNA in the clinical
laboratory for the diagnosis of invasive infections, particularly in resource-limited
settings. The findings that the K2EDTA blood collection tube combined with single-spin
low-speed plasma separation and 24-h processing delay yields the maximum amount
of amplifiable cfDNA for 3 out of 4 pathogens we evaluated implies that optimized
preanalytical steps can be feasibly and inexpensively implemented in the routine
microbiology laboratory workflow, both in resource-rich and resource-limited settings.
Unlike Streck and PAXgene cfDNA blood collection tubes, which cost about $10 each,
K2EDTA tubes cost less than $0.50. Similarly, the findings that 25 mM EDTA preserves
pathogen cfDNA in whole urine without the need to remove cellular debris with
centrifugation and up to a 24-h processing delay implies that optimized preanalytical
steps can be inexpensively operationalized for pathogen cfDNA testing in urine.
Although the findings of this study are promising, a better understanding of the
underlying biochemical basis of preanalytical factors impacting cfDNA recovery may
lead to further optimization and improvement of cfDNA testing. The finding that the
K2EDTA blood collection tube was superior to the Streck and PAXgene tubes for the
FIG 8 Comparison of small- and large-volume plasma and urine for detection of M. tuberculosis cfDNA
using contrived samples and tuberculosis patient samples. (A and C) Spiked plasma (A) and urine (C)
samples from five healthy donors (unique symbols). Blood samples were collected in a K2EDTA tube, and
urine samples were preserved with 25 mM EDTA. Blood and urine samples were spiked with short
fragments of DNA from M. tuberculosis at the highest detectable dilution (open symbols) and at 10-fold
higher concentration (filled symbols). (B and D) K2EDTA plasma (n 12) (B) and Tris-EDTA urine (n 10)
(D) samples from tuberculosis patients with detectable cfDNA. IS6110 PCR was performed on cfDNA
extracts, and CT values were plotted. Unpaired symbols indicate that a positive result was only observed
with a larger volume.
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recovery of cfDNA from M. tuberculosis, S. enterica, and EBV after delayed processing
may be explained by EDTA (1.8 mg/ml) in K2EDTA, which protects pathogen cfDNA
from endogenous DNase activity in blood (31). Whether increasing the EDTA concen-
tration by as much as 10-fold, as suggested by Barra and colleagues to fully inhibit
endogenous DNase activity (31), can further increase the yield of pathogen cfDNA
remains to be shown. Another interesting finding was that more A. fumigatus cfDNA
was recovered from PAXgene tubes than from K2EDTA tubes. Whether this can be
reproduced in patients with invasive fungal disease and the molecular basis of this
result have important implications for the sensitivity of cfDNA assays used to diagnose
invasive fungal disease (13, 15). We also observed a higher pathogen cfDNA yield after
single-spin plasma separation than with double-spin separation. The molecular basis
underlying this finding is unclear, but understanding it may facilitate designing a novel
tube with higher cfDNA yield. Last, the difference in urine cfDNA stability between
pathogens is intriguing. While M. tuberculosis and S. enterica cfDNA were rapidly
degraded in unpreserved urine, A. fumigatus and EBV cfDNA was less prone to degra-
dation. Whether this is due to differences in DNA packaging between prokaryotic and
eukaryotic organisms remains to be determined.
This study has several limitations. First, although the variables investigated using TB
patient samples in this study correlated very well with findings from contrived samples,
not all findings from contrived samples could be confirmed. As such, further studies are
needed to validate our findings with clinical samples. Second, although many of the
findings with spiked samples were statistically significant, there was an overlap be-
tween groups in most cases. Thus, the clinical significance of our findings needs to be
further investigated in clinical studies. Third, we did not include a serum collection tube
to compare serum to plasma for the recovery of pathogen cfDNA. This was because
serum has been shown to have 15-fold higher endogenous nuclease activity and a
smaller fraction and quantity of tumor and fetal cfDNA, respectively, than with plasma
(25, 31). Importantly, the sensitivity of Aspergillus PCR was shown to be higher in plasma
than in serum (94.7% versus 68.4%, respectively) (13). We also did not investigate
heparin as the anticoagulant for plasma because older studies had shown that it
inhibits PCR (32–34). Fourth, we did not investigate processing delays beyond 24 h.
However, 24 h is a sufficient time period to collect and transport samples to the
laboratory for processing in most institutions. Last, we did not compare extraction
methods for pathogen cfDNA. This was the topic of investigation of a recent study that
evaluated commercial methods available for the extraction of plasma cfDNA (35). A key
finding from this study was that commercial methods are biased toward longer cfDNA.
Further studies are needed to investigate and optimize the extraction of pathogen
cfDNA from plasma and urine.
In summary, we evaluated preanalytical factors impacting the recovery of pathogen
cfDNA from blood and urine and found that large-volume single-spin K2EDTA-plasma
and EDTA-whole urine with up to a 24-h processing delay represent good choices for
pathogen cfDNA. Future studies can focus on measuring the performance of pathogen
cfDNA assays using optimized preanalytical factors described here. It is likely that more
efficient pathogen cfDNA extraction methods and sensitive cfDNA NAATs, ideally,
sample-to-answer tests, are needed to complement the preanalytical optimization
steps described in this study in order to move noninvasive diagnosis of invasive
infections into routine practice.
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